Marker Therapeutics is trading at $0.91, down 10.25%, with the decline likely reflecting broad risk-off sentiment and biotech-sector pressure rather than a new company-specific event.
- No November 5 company-specific announcement was found; its press-release page lists October 19 as the latest release.
- The supplied context reports a sharp market sell-off and a 5.19% drop in biotech ETF XBI, supporting sector/global sentiment as the likelier explanation.